机构

• 上海药物研究所 [33]
• 合肥物质科学研究院 [3]

采集方式

• OAI收割 [36]

内容类型

• 期刊论文 [36]

发表日期

• 2025 [6]
• 2024 [11]
• 2023 [4]
• 2022 [8]
• 2021 [6]
• 2020 [1]
• 更多

学科主题

筛选

浏览/检索结果: 共36条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序作者升序作者降序题名升序题名降序发表日期升序发表日期降序 Discovery of indole derivatives as STING degraders 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 卷号: 294, 页码: 21 作者:  An, Yuxiang;  Zhang, Yan;  Luo, Xin;  Lan, Yaohan;  Geng, Meiyu   |  收藏  |  浏览/下载：1/0  |  提交时间：2025/08/20 Autoimmune diseases  Degrader  Inflammatory  PROTAC  STING   An overview of PROTACs targeting KRAS and SOS1 as antitumor agents 期刊论文  OAI收割 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2025, 卷号: 125, 页码: 13 作者:  Han, Zhiqiu;  Wu, Qianping;  Rao, Hongxin;  Xu, Tianfeng;  Zhou, Chuan   |  收藏  |  浏览/下载：5/0  |  提交时间：2025/08/20 KRAS  SOS1  PROTAC  Antitumor agent   Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling 期刊论文  OAI收割 JOURNAL OF PHARMACEUTICAL ANALYSIS, 2025, 卷号: 15, 期号: 5, 页码: 15 作者:  He, Yifei;  Zhu, Chenggu;  Lei, Peng;  Yang, Chen;  Zhang, Yifan   |  收藏  |  浏览/下载：1/0  |  提交时间：2025/08/20 PROTAC  Vepdegestrant (ARV-471)  Radiolabeling  In vitro-in vivo extrapolation (IVIVE)  Physiologically based pharmacokinetic  (PBPK) model   Recent advances in targeted degradation in the RAS pathway 期刊论文  OAI收割 FUTURE MEDICINAL CHEMISTRY, 2025, 卷号: 17, 期号: 6, 页码: 693-708 作者:  Ge, Zhiming;  Fan, Zisheng;  He, Wei;  Zhou, Guizhen;  Zhou, Yidi   |  收藏  |  浏览/下载：14/0  |  提交时间：2025/04/24 RAS  cancer  mutation  degrader  PROTAC   Self-Oxygenating PROTAC Microneedle for Spatiotemporally-Confined Protein Degradation and Enhanced Glioblastoma Therapy 期刊论文  OAI收割 ADVANCED MATERIALS, 2025, 页码: 13 作者:  Jiang, Xingyu;  Lai, Yi;  Xia, Wenzheng;  Yang, Wenfang;  Wang, Junjue   |  收藏  |  浏览/下载：18/0  |  提交时间：2025/04/24 acid-activatable photodynamic therapy  double-layered microneedle  glioblastoma therapy  light-activatable PROTAC prodrug  protein degradation   Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2025, 卷号: 15, 期号: 3, 页码: 1659-1679 作者:  Jin, Yuheng;  Qi, Xuxin;  Yu, Xiaoli;  Cheng, Xirui;  Chen, Boya   |  收藏  |  浏览/下载：19/0  |  提交时间：2025/06/23 HDAC7  PROTAC  Selectivity  Hematologic malignancies  Non-enzymatic function   Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer 期刊论文  OAI收割 BIOORGANIC CHEMISTRY, 2024, 卷号: 153, 页码: 16 作者:  Nie, Hui-Jun;  Li, Ben-Fu;  Sun, Jingya;  Yuan, Yali;  Zhang, Zhi-Gao   |  收藏  |  浏览/下载：44/0  |  提交时间：2024/11/26 Triple-negative breast cancer  Targeting transcription regulation  Orally bioavailable degrader  PROTAC  Cyclin-dependent Kinase 9   Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2024, 卷号: 14, 期号: 12, 页码: 5382-5392 作者:  Liu, Lu;  Qiu, Yuanlai;  Suo, Yuying   |  收藏  |  浏览/下载：21/0  |  提交时间：2025/04/01 N 6-Methyladenosine  FTO  PROTAC  RNA epigenetics  Antileukemia   Discovery of KW0113 as a First and Effective PROTAC Degrader of DNMT1 Protein 期刊论文  OAI收割 CHEMMEDCHEM, 2024, 页码: 16 作者:  Wang, Huihui;  Wang, Zhaoliang;  Hu, Linghao;  Yang, Bingjie;  Zong, Liangyi   |  收藏  |  浏览/下载：30/0  |  提交时间：2024/12/16 Degrader  DNMT1  DNA methylation  PROTAC   Liver-targeting chimeras as a potential modality for the treatment of liver diseases 期刊论文  OAI收割 JOURNAL OF CONTROLLED RELEASE, 2024, 卷号: 374, 页码: 627-638 作者:  Chen, Chuanjie;  Pan, Yongzhang;  Yang, Xiaoyu;  Li, Huiqin;  Cai, Xinhui   |  收藏  |  浏览/下载：40/0  |  提交时间：2024/10/21 ASGPR  BET  Hepatocellular carcinoma  LIVTAC  On-target toxicity  PROTAC